Press Releases Oculis Holding AG

Equities

OCS

CH1242303498

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
12.01 ^USD	-1.23%		-0.50%	+6.95%

May. 08	Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oculis updates share capital for its existing at-the-market offering program	May. 17	GL
Oculis : Entry into Sales Agreement with Leerink Partners, LLC - Form 6-K	May. 08	PU
Oculis : Form 6-K	May. 08	PU
Oculis Reports Q1 2024 Financial Results and Provides Company Updates	May. 08	GL
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis	May. 08	AQ
Oculis Publishes Invitation to the Annual General Meeting	May. 07	GL
Oculis to Present at Bank of America Global Healthcare Conference	May. 06	AQ
Oculis Publishes Invitation to the Annual General Meeting	Apr. 29	AQ
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market	Apr. 22	GL
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market	Apr. 11	AQ
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development	Apr. 10	AQ
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	Apr. 08	AQ
Oculis to Participate at Upcoming April Investor Conferences	Apr. 04	AQ
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress	Mar. 18	AQ
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments	Feb. 28	AQ
Oculis to Present at Upcoming February Investor Conferences	Jan. 29	AQ
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024	Jan. 22	AQ
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	Dec. 20	AQ
Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema	Dec. 18	AQ
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease	Dec. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oculis Holding AG

Equities

OCS

CH1242303498

Press Releases

Filters